547 related articles for article (PubMed ID: 15083599)
1. Vitamin D analogs as therapeutic agents: a clinical study update.
Wu-Wong JR; Tian J; Goltzman D
Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J
Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
Wu-Wong JR; Tian J; Nakane M; Ma J; Fey TA; Kroeger P; Fryer RM; Reinhart GA
Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
[TBL] [Abstract][Full Text] [Related]
5. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Brown AJ; Slatopolsky E
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
[TBL] [Abstract][Full Text] [Related]
6. Are vitamin D receptor activators useful for the treatment of thrombosis?
Wu-Wong JR
Curr Opin Investig Drugs; 2009 Sep; 10(9):919-27. PubMed ID: 19705334
[TBL] [Abstract][Full Text] [Related]
7. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
Goldenberg MM
Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D analogs: therapeutic applications and mechanisms for selectivity.
Brown AJ; Slatopolsky E
Mol Aspects Med; 2008 Dec; 29(6):433-52. PubMed ID: 18554710
[TBL] [Abstract][Full Text] [Related]
9. 1alpha,25-dihydroxyvitamin D3 inducible transcription factor and its role in the vitamin D action.
Nezbedova P; Brtko J
Endocr Regul; 2004 Mar; 38(1):29-38. PubMed ID: 15147236
[TBL] [Abstract][Full Text] [Related]
10. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease.
Wolf M; Thadhani R
Semin Dial; 2005; 18(4):302-6. PubMed ID: 16076353
[TBL] [Abstract][Full Text] [Related]
11. Vascular calcification in chronic kidney failure: role of vitamin D receptor.
Wu-Wong JR; Melnick J
Curr Opin Investig Drugs; 2007 Mar; 8(3):237-47. PubMed ID: 17408120
[TBL] [Abstract][Full Text] [Related]
12. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D treatment in chronic kidney disease.
Andress DL
Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
15. [Recent progress of study on vitamin D analogs].
Kittaka A; Saito N; Takano M
Clin Calcium; 2006 Jul; 16(7):1154-65. PubMed ID: 16816476
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D analogs: novel therapeutic agents for cardiovascular disease?
Reinhart GA
Curr Opin Investig Drugs; 2004 Sep; 5(9):947-51. PubMed ID: 15503649
[TBL] [Abstract][Full Text] [Related]
17. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.
Jones G; Hogan DB; Yendt E; Hanley DA
CMAJ; 1996 Oct; 155(7):955-61. PubMed ID: 8837546
[TBL] [Abstract][Full Text] [Related]
18. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D receptor ligands for osteoporosis.
Cheskis BJ; Freedman LP; Nagpal S
Curr Opin Investig Drugs; 2006 Oct; 7(10):906-11. PubMed ID: 17086935
[TBL] [Abstract][Full Text] [Related]
20. [Vitamin D metabolism and current options for therapeutic activation of vitamin D receptor in patients with chronic kidney disease or renal failure].
Dusilová Sulková S
Vnitr Lek; 2012 Nov; 58(11):839-49. PubMed ID: 23256830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]